Top Life Science Events Worldwide: Category-Wise Guide for 2026–2027

Congress dates are fixed years ahead, but the deadline that drives your slides is not

A medical congress is where new clinical data goes public, where deals start and where brands are judged slide by slide. The event calendar is fixed years ahead, and it decides when abstracts, posters, decks and booth content must exist.

This guide groups more than 40 top life science events by category. For each one you get the dates, the city, who attends and who benefits most. Use it to decide where to present, where to exhibit and where to meet partners or investors.

How we picked these events: we started from A1 Slides' calendar research of about 60 congresses and trade shows, each checked on the organiser's own site, then kept the events with the largest audiences, the most influential data releases or the strongest deal-making role in each category.

Eleven categories cover the events that matter to life science teams

1. Oncology and haematology: the largest audiences and the most market-moving readouts

Who benefits most: medical affairs and publications teams (posters, oral decks, encores), brand teams (booths, satellite symposia), investor relations (readout decks) and the medcomms agencies supporting all of them.

Why ASH is the production peak of the year. ASH asks every poster presenter for a poster PDF and a pre-recorded, narrated PowerPoint of 3–5 minutes. The deadline for slides, posters and recordings is 16 November 2026, 26 days before the meeting. Late uploads are marked unavailable, and the presenter must print their own poster. For a meeting with 5,000+ abstracts (2024), that is a short production window.

Why ASCO is the biggest stage. ASCO leads on attendance and countries. Its production chain runs from abstract submission, which opens on 4 November 2026 and closes on 26 January 2027, to draft slide decks from oral presenters in mid-May 2027, about three weeks before the meeting (the equivalent deadline in 2025 was 12 May, 18 days before that meeting).

2. Cardiovascular, diabetes and metabolic: obesity and diabetes data now move markets as sharply as oncology

Who benefits most: cardiometabolic brand and medical teams with late-breaking trial data, device companies launching new technology, and investor-relations teams, since readouts here are highly market-sensitive.

3. Neurology and neurodegeneration: where Alzheimer's, MS, migraine and epilepsy data reach specialists and investors

Who benefits most: CNS-focused biotech presenting early or pivotal data, diagnostics companies with new biomarkers, and medical affairs teams building late-breaking decks under embargo.

4. Immunology, rheumatology and respiratory: poster-heavy meetings with high visual volume

Who benefits most: immunology and respiratory brand teams, publication planners managing many posters, and companies re-presenting data as encores across the US and European meetings.

5. Infectious disease, vaccines and HIV

Who benefits most: vaccine and anti-infective companies, diagnostics firms and public-health partners. ESCMID's rules are strict: a 350-word abstract limit, a maximum of three figures or tables, and no AI-generated data or results.

6. Biotech partnering and investor events: corporate and investor decks, not scientific posters

Who benefits most: founders and CEOs raising capital, BD teams out-licensing assets, and investor-relations teams.

7. Pharma manufacturing and supply chain: exhibition-first events

Who benefits most: CDMOs, API manufacturers and equipment suppliers, especially Indian exporters. Booth graphics and capability decks matter more than abstracts here. At CPHI, two of three stand types require exhibitors to supply their own graphics.

8. Medtech, imaging and diagnostics trade fairs

Who benefits most: medtech and diagnostics companies seeking distributors, imaging and AI firms launching products, and exporters entering Europe or the Middle East.

9. HEOR and market access

Who benefits most: value and access teams, HEOR consultancies and real-world-evidence firms. ISPOR is poster-dominant and requires PowerPoint in 16:9, yet it provides no template, so every presenter builds their own.

10. Clinical operations and regulatory

Who benefits most: CROs and trial-technology vendors winning sponsors, and regulatory teams. These events are session-driven, so speaker decks matter more than posters. For the bid side of this audience, see our guide to the CRO bid defence deck.

11. Medical affairs, publications and pharma market research

Who benefits most: medcomms and market-research agencies, and the in-house teams who run congress, MSL and debrief programmes.

November 2026 has the most events; June 2027 has the tightest cluster of major congresses

Nine events in this guide start in November 2026: AHA, ACR Convergence, ISPOR Europe, BIO-Europe, MEDICA, CTAD, Jefferies London, CPHI & PMEC India and RSNA (which starts on 29 November). The densest collision is 6–11 November, when AHA, ACR, ISPOR Europe and BIO-Europe all fall inside six days. June 2027 is the heaviest month for large congresses, with ASCO, BIO, EULAR, EHA, ADA, EPHMRA and DIA within four weeks.

Pick the event by role, not by size

For role-specific deck guidance, see our pages on medical affairs presentation design, MSL slide deck design and biotech investor deck design.

Six steps keep a congress deck inside every organiser's rules

A life science deck is a compliance object as much as a design job. Abstracts lock three to seven months out (AAN 6.5 months, ASCO and ASH about 4.5, EHA about 3.3), and the deadline for slides and posters comes much later.

Track two deadlines, not one. Only ASH, SABCS and ASCO publish a slide or poster deadline among the events in this guide, 18 to 26 days before the meeting. Everyone else leaves a three-to-four-week window that is not published. Plan to finish slides and posters at least three to four weeks before the meeting.

Build for the internal review gates. ASCO collects draft slides from oral presenters in mid-May so the discussant can prepare, then takes final slides four hours before the session. Your real deadline is the draft, not the final.

Follow each congress's format rulebook. ASCO requires PowerPoint and offers two official widescreen templates. ISPOR requires PowerPoint in 16:9 but provides no template. ESMO's oral-presenter instructions accept .pptx only, reject Keynote files, cap a 10-minute talk at 12 slides and ban sponsor branding.

Get the clinical charts right. A 2024 analysis of 641 phase III oncology trials in The Oncologist found that 116 (18%) had missing visual elements in their Kaplan-Meier plots, defined as an incomplete y-axis range or no number-at-risk table. Only 15 of 574 trials (3%) with surrogate-endpoint plots met every interpretability criterion, which included reporting the number of censored patients and matching the disease-assessment interval to the number-at-risk interval. Industry-sponsored and larger trials were less likely to have missing elements. A complete y-axis, a number-at-risk table and censoring counts are not optional. For the full method, see our clinical data visualization playbook and our guide to using charts and graphs effectively in presentations.

Plan disclosures and embargoes from day one. ESMO treats the disclosure slide as mandatory even with nothing to declare. The GPCAP recommendations for company-sponsored conference material cover authorship, contributorship and financial transparency for abstracts, posters and slides. Late-breaking data is often built under embargo, so limit who sees drafts.

Design once, reuse as encores. The same dataset is often re-presented at a second congress (an encore), for example ASCO then EHA or ESMO. A modular master deck makes reformatting fast and consistent.

Where A1 Slides fits: the production layer behind these events

The events above are where the work is judged. A1 Slides is not one of them and is not ranked in any list on this page. We are the production layer for the teams who attend: medical affairs, publications, brand, BD and investor-relations teams, and the medcomms and consulting firms that support them.

A1 Slides designs medical affairs and MSL decks, oral presentation decks, corporate and investor decks, and ghost decks for pharma, biotech, medtech, CRO and medcomms teams. Work is formatted to the organiser's template and rules, with accurate Kaplan-Meier, forest and mechanism-of-action visuals, and briefs handed over in your evening come back finished by morning across time zones.

Planning for ASH, ASCO, JPM or BIO? Start with the 3-Slide Challenge before the visual deadline arrives.

Frequently asked questions

Sources and method

Event dates, venues and scale figures come from A1 Slides' calendar research, with each date opened on the organiser's own site and re-checked by a second reviewer in October 2026. ESMO 2026 dates come from the venue operator, IFEMA. Three medtech events (MEDICA, RSNA, WHX Dubai) were added and checked on 15 October 2026. CROI 2027 dates are labelled preliminary by the organiser. BIO-Europe gives two attendance figures (5,800+ and 8,000+) and the lower one is used here. Always confirm on the official site before booking.